Compliance with the Current NCCN Guidelines and Its Critical Role in Pancreatic Adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Laboratory medicine"
DOI: 10.1093/labmed/lmac046
Abstract: OBJECTIVES Since 2019, the National Comprehensive Cancer Network (NCCN) has recommended genetic testing for patients diagnosed with pancreatic adenocarcinoma that includes universal germline testing and tumor gene profiling for metastatic, locally advanced, or recurrent disease.… read more here.
Keywords: tumor gene; germline testing; compliance; nccn guidelines ... See more keywords
Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy
Sign Up to like & getrecommendations! Published in 2017 at "Oncology Research and Treatment"
DOI: 10.1159/000481353
Abstract: The identification of human Wilms' tumor gene 1 (WT1) protein-derived cytotoxic T lymphocyte (CTL) epitopes and the in vivo efficacy of WT1 peptide-based immunotherapy in a mouse model were reported in 2000. This successful basic… read more here.
Keywords: tumor gene; clinical studies; peptide vaccine; vaccine ... See more keywords
Gene mutation in cancer patients with diabetes: a real-world retrospective cohort study
Sign Up to like & getrecommendations! Published in 2025 at "BMC Cancer"
DOI: 10.1186/s12885-025-14511-3
Abstract: Diabetes mellitus (DM) exhibits a strong association with tumorigenesis, yet its impact on tumor gene mutations remains poorly understood. Consequently, the present study was conducted to delve into the influence of DM on tumor gene… read more here.
Keywords: cancer; gene mutations; tumor gene; gene ... See more keywords
Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic markers and tumor gene expression by mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.5_suppl.146
Abstract: 146 Background: Mevrometostat (PF-06821497; M) is a potent and selective small molecule inhibitor of EZH2. Dose exploration of M in combination with enzalutamide (E) showed a manageable safety profile and promising activity in patients with… read more here.
Keywords: combination; gene expression; tumor; tumor gene ... See more keywords